Skip to main content
RYTM
NASDAQ Life Sciences

Rhythm Pharma's IMCIVREE Secures EU Marketing Authorization for Hypothalamic Obesity

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$81.37
Mkt Cap
$5.556B
52W Low
$55.31
52W High
$122.2
52W Position info
47% above low
Off High info
33% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

RYTM sits 47% above its 52-week low of $55.31.

Summary

Rhythm Pharmaceuticals announced that its drug, IMCIVREE (setmelanotide), has received marketing authorization from the European Commission. This approval is for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity. This significant regulatory milestone opens up the European market for IMCIVREE in a specific, high-need indication, potentially driving new revenue streams for the company. This follows the company's strong 2025 annual report, which highlighted revenue growth and a solid cash position. Investors will now watch for the commercial launch plans and initial sales figures in the EU.

At the time of this announcement, RYTM was trading at $81.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $55.31 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $105.00 info
Change: -$4.75 (-4%) info
Market Cap: $7.281B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $105.00 info
Change: +$9.79 (+10%) info
Market Cap: $7.281B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $105.00 info
Change: +$19.30 (+23%) info
Market Cap: $7.281B info
RYTM
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $88.42
Real-time Price: $105.00 info
Change: +$16.58 (+19%) info
Market Cap: $7.281B info
RYTM
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $86.44
Real-time Price: $105.00 info
Change: +$18.56 (+21%) info
Market Cap: $7.281B info